- Home
- WFC vs NVO Comparison
WFC vs NVO Comparison
Compare WFC & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFC
- NVO
- Stock Information
- Founded
- WFC 1852
- NVO 1923
- Country
- WFC United States
- NVO Denmark
- Employees
- WFC N/A
- NVO N/A
- Industry
- WFC Major Banks
- NVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WFC Finance
- NVO Health Care
- Exchange
- WFC Nasdaq
- NVO Nasdaq
- Market Cap
- WFC 248.8B
- NVO 278.0B
- IPO Year
- WFC N/A
- NVO N/A
- Fundamental
- Price
- WFC $82.35
- NVO $69.81
- Analyst Decision
- WFC Buy
- NVO Buy
- Analyst Count
- WFC 18
- NVO 3
- Target Price
- WFC $78.08
- NVO $112.00
- AVG Volume (30 Days)
- WFC 18.1M
- NVO 8.8M
- Earning Date
- WFC 07-15-2025
- NVO 08-06-2025
- Dividend Yield
- WFC 1.94%
- NVO 1.69%
- EPS Growth
- WFC 16.01
- NVO 17.93
- EPS
- WFC 5.57
- NVO 3.40
- Revenue
- WFC $77,254,000,000.00
- NVO $43,922,211,349.00
- Revenue This Year
- WFC $7.94
- NVO $18.59
- Revenue Next Year
- WFC $4.82
- NVO $15.61
- P/E Ratio
- WFC $14.79
- NVO $20.52
- Revenue Growth
- WFC N/A
- NVO 24.11
- 52 Week Low
- WFC $50.15
- NVO $57.00
- 52 Week High
- WFC $82.40
- NVO $143.69
- Technical
- Relative Strength Index (RSI)
- WFC 73.68
- NVO 46.24
- Support Level
- WFC $78.96
- NVO $68.12
- Resistance Level
- WFC $76.76
- NVO $70.42
- Average True Range (ATR)
- WFC 1.34
- NVO 1.50
- MACD
- WFC 0.63
- NVO -0.83
- Stochastic Oscillator
- WFC 99.49
- NVO 20.18
About WFC Wells Fargo & Company
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company has four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the US
About NVO Novo Nordisk A/S
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.